Use of a cross circulation platform to regenerate lungs with induced gastric injury

Lung transplantation is a therapeutic option for patients with end-stage lung disease for which no other treatments exist. Since 2012, the number of new candidates added to the wait list and the number of lung transplantations performed in the United States has increased (1). Despite an increase in the number of lung donor counts by 13.9% from 2015–2016, the overall mortality rate for candidates listed for lung transplant is 17.2 per 100 wait-list years (1,2).